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ABSTRACT 
 
Well understood are the adaptive and dramatic neutralizing homosubtypic antibody responses to 
hypervariable, immunodominant sites of the hemagglutinin (HA) and neuraminidase (NA) of 
individual influenza strains. These define influenza subtypes and vaccines modelled upon their HA 
and NA antigens provide seasonal neutralizing antibody protection against subsequent exposure to 
the strain and its close relatives, but give little if any protection against antigenically drifted or 
shifted strains. Contrasting to this is a different form of acquired antibody response, called 
heterosubtypic immunity. This provides a more seasoned adaptive antibody response to immune-
recessive epitopes that are highly-conserved amongst strains. Although, such responses are of lower 
individual amplitudes than seasonal mechanisms they are active across influenza subtypes, and may 
give pre-emptive protection against new strains yet to emerge. Heterosubtypic immunities have 
been well studied in animals, but surprisingly there is minimal evidence for this type of antibody 
immunity in humans. Thus championed is the notion that seasoned humoral responses can through 
repeated exposure to sites widely conserved across different strains, cumulatively provide humans 
with a level of broad protection against emergent novel strains, such as H5N1, that is not afforded 
by seasonal humoral responses. 
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INTRODUCTION 
 
With a mortality up to 250 times greater than strains that 
cause epidemics the lethality of the 1918 avian H1N1 
influenza pandemic is frequently reported (Palese et al, 
2006; Taubenberger and Morens, 2006), but seldom 
appreciated is the fact that the majority (>97%) of those 
infected survived, amounting to 0.8-2 billion lives 
recovered. The most profound defence against influenza is 
provided by adaptive immunity that is mediated by 
neutralizing strain-specific “seasonal” antibodies directed 
against highly variable naïve antigens of an infecting 
influenza. But this is a post-emergent process that 
optimally takes weeks to months for full development 
(Murphy et al, 1982; Couch and Kasel, 1983; Edwards et 
al, 1986), and consequently beyond the time-frame of 
primary infection, viral shedding and disease development 
and is incapable of protecting against the first appearance  
© The Authors | Journal of Molecular and Genetic Medicine | December 2009 | Vol 3, No 2 | 205-209 | OPEN ACCESS 
206
of a new influenza strain. Therefore, additional 
mechanisms of protection need to be invoked to explain 
the mass herd immune protection of the community. 
Clearly, innate and heterosubtypic cellular immune 
mechanisms are involved in this; however, these alone are 
insufficient to justify this level of protection against a 
pandemic influenza, and prompt the issue of whether 
acquired heterotypic antibody immunity may provide a 
missing link in immune protection. Heterosubtypic cellular 
and antibody immune responses have been realized and 
studied for almost fifty years (Kilbuorne and Schulman, 
1965), with extensive examination in animal models of 
influenza infection (reviewed in, Epstein, 2003; Grebe et 
al, 2008). There has been considerable study and 
demonstration of heterosubtypic cell-mediated immunity 
in humans as an essential component of systematic 
immune protection, and recent evaluation of its cross-
protective vaccine potential (Doherty and Kelso, 2008). 
However, this is not the focus of this present review. In 
striking contrast to cell-mediated responses, until recently, 
there has been minimal study or direct evidence for 
heterosubtypic antibody immunity in humans, or 
resolution of protective heterosubtypic antibodies, or their 
partnering conserved influenza epitopes (i.e., protectopes; 
Plotnicky-Gilquin et al, 1999) (Bui et al, 2007; Ekiert et al, 
2009; Sui et al, 2009). It is, therefore, proposed that akin 
to the heterosubtypic processes shown in animals, human 
antibody memories become acquired with age, from 
repeated infections and stimulus by highly-conserved 
influenza antigens. Despite being immunorecessive, this 
systematically leads to a broad “seasoned” heterosubtypic 
protection from antibodies that target equivalent sites of 
new strains. Thus it is important to identify whether or not 
such core antibody responses across influenzas do in fact 
provide significant immune protection against novel 
influenzas, such as avian H5N1 and evolving 2009 H1N1. 
 
H5N1 influenza has had a higher measured mortality than 
the 1918 H1N1 influenza, albeit with recovery of 
approximately 40% of individuals surviving infection. 
Epidemiologic studies indicate an age-related protection 
with survival of approximately 60% of individuals over the 
age of 40 years compared to less than 25% for individuals 
in the 10-20 years age group (Smallman-Raynor and Cliff, 
2007). Similarly data from the 1918 H1N1 and 1957 H2N2 
pandemics also indicate a greater level of protection in 
adults (Luk et al, 2001; Epstein, 2006), which may have 
reduced the impact in the adult sub-population older than 
65 years to that of seasonal epidemics. While apparent 
protection of the elderly may result from earlier 
immunization of this cohort from exposure to a like virus, 
we believe it is equally plausible to result from a lifetime 
acquired heterosubtypic immunity, or even a combination 
of both. As seasonal antibodies provide the main correlate 
of homotypic neutralizing protection against influenza 
(Schild et al, 1975; Virelizier, 1975; Delem and Jovanovic, 
1978; Kashyap et al, 2008), we now raise the question of 
whether seasoned, cross-reactive antibodies similarly 
provide a significant contribution for heterosubtypic 
protection. Certainly, our own findings implicate a pre-
existing pool of anti-influenza antibodies in an unexposed 
Australian population that can protect against avian H5N1 
influenza, in vitro, along with H5-hemagglutinin binding 
antibodies that are most prominent with adult age (Lynch et 
al, 2008; Stelzer-Braid et al, 2008). This is also supported 
by observations of cross-reactive anti-neuraminidase 
antibodies from unexposed humans that partially protect 
H5N1 infected mice (Sandbulte et al, 2007). The idea of a 
role for low levels of pre-existing crosstypic antibodies in 
some humans to protect against foreign emerging influenza 
strains is indeed attractive. This would be supported by the 
other arm of heterosubtypic immunity, namely human 
cross-typic cell-mediated immunity, for which there is far 
more substantial evidence of protection against H5N1 
pathogenesis and death (Jameson et al, 1999; Kreijtz et al, 
2008; Lee et al, 2008; Roti et al 2008). A general overview 
of the combined human cellular and humoral system arms 
of heterosubtypic immunity and support evidence is 
provided in Figure 1. 
 
The indication that heterosubtypic H5N1 neutralizing 
antibodies in unexposed individuals could be bolstered 
by a seasonal vaccine (Gioia et al, 2008) is encouraging. 
However, in general seasonal vaccines have not been 
reported to give wider immunity for emerging strains, 
such as the avian H5N1, or the 2009 H1N1 pandemic 
influenzas (Kelly and Grant, 2009). We believe that this 
marked discrepancy is mainly due to the nature and size 
of the protective responses. Seasonal vaccines promote a 
substantial neutralizing response, mainly directed against 
the globular head region of hemagglutinin (HA) for cell 
receptor binding and neuraminidase (NA) for viral egress 
from an infected cell. In contrast, seasoned responses 
would by definition promote many lesser responses to 
multiple protein sites, including most, if not all, surface 
and interior proteins of influenza viruses. We predict this 
would individually go undetected, or be in the 'grey zone' 
of current in vitro assays. However, we propose that the 
net effect of marshalling the combined heterosubtypic 
systems responses would result in in vivo protection that 
could be measured and modelled. As a result we suggest 
that although seasonal and seasoned responses may 
appear discordant they would effectively champion one 
another, and ultimately enable both specific and 
universal protective capabilities to ideally reduce the 
debilitating and lethal effects of influenza to at least one 
of mild illness. 
 
The requirements for vaccines to promote heterosubtypic 
antibody responses to conserved sites of influenza proteins 
for broad, seasoned, possibly universal protection would 
need to be inherently different from current seasonal 
vaccines: The latter express hypervariable determinants 
and promote high-tire antibody responses to homotypic 
immune dominant determinants of the HA globular-head 
to block cell receptor binding and neutralize infection. The 
challenge therefore is to separately design seasoned 
vaccines capable of promoting broad heterosubtypic 
protection against drifted and new zoonotic (avian) strains. 
Unlike seasonal vaccines that disrupt influenza-cell 
binding, a combination of seasoned vaccine approaches 
would likely be required to stimulate both antibody and T-
cell responses to multiple conserved epitopes widely 
expressed across human and avian (e.g., H5N1) 
influenzas, and be accessible to antibodies or drugs to 
disrupt all aspects of the infection. Valuable insights 
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Antibody & T cell epitope targets 
conserved in human (H1N1, H3N2) 
and avian H5N1 strains
(Thomas et al EID2006; Bui et al PNAS 2007)
Antibody Protection of Infection T-Cell Protection of Disease & Death 
1918 > 97% survived H1N1
2009 >40% survived H5N1
Heterosubtypic Human Immunity to Avian (H5N1) Influenza
Target proteins: HA, NA, M2, NP Target proteins: NP, M1, PA, PB1, HA, NA 
Crosstypic human antibodies to 
H5N1 proteins and in vitro 
neutralization
(Sandlbute et al PLoS Med 2007; Lynch et 
al OIJ 2008; Stelzer-Braid et al CJV 2008)
Anti-NA/NP antibodies and 
seasonal human vaccine 
protect H5N1 infected mice 
(Tumpey et al JV 2001; Ichinohe et al JID 
2007; Sandlbute et al PLoS Med 2007; 
Carragher et al JI 2008)
Seasonal vaccine
boosts human cross-
protective anti-H5N1 
antibodies
(Gioia et al EID 2008)
Evidence
Other antivirals: 
Relenza, Tamiflu, etc
To protect the young, the aged, 
immune naive or compromised
Hyperimmune crosstypic
antibody for passive transfer
Hyperimmune crosstypic
cell based therapies
Conserved  antibody and T-cell 
epitope vaccines
+Convalescent neutralizing 
antibodies/B-cells
(Kong et al PNAS 2006;  Luke et al AIM 2006; 
Simmons et al PLoS Med 2007; Zhou et al
NEJM 2007; Kayshap et al PNAS 2008)
Therapeutic value Therapeutic value
Crosstypic cytotoxic T-
lymphocytes (CTL) to H5N1 
in humans 
(Jameson et al JI 1999; Kreitz et al JV 
2008; Lee et al JCI 2008; Roti et al JI 
2008;) 
Seasonal vaccine boosts 
human crosstypic anti-H5N1 T-
cell responses
(Ichinohe et al JID 2007; Gioia et al EID 2008)
NP and human vaccines 
protect mice from H5N1
(Roy et al Vacc 2007) 
Evidence
 
 
Figure 1. Schematic representation of the humoral and cell-mediated systems of heterosubtypic immunity for the delivery of cross-
strain protection of novel influenzas, such as avian H5N1, via the targeting of cell-free virions and influenza protein expressing 
infected-cells. Both arms work in concert to protect against viral infection and propagation, pathogenesis and death. Shown is an 
overview of the respective mechanisms, the proteins they target, evidence of their cross-protective power, and avenues for the 
development of heterosubtypic-based vaccine and antiviral interventions for broad based influenza protection. [References: Jameson 
et al, 1999; Tumpey et al, 2001; Kong et al, 2006; Luke et al, 2006; Ichinohe et al, 2007; Roy et al, 2007; Sandlbute et al, 2007; 
Simmons et al, 2007; Zhou et al, 2007; Carragher et al, 2008; Gioia et al, 2008; Kayshap et al, 2008; Kreitz et al, 2008; Lee et al, 
2008; Lynch et al, 2008; Roti et al, 2008; Stelzer-Braid et al, 2008] 
    
 
 
into conserved linear and conformational antibody and T-
cell epitopes of human and avian influenza proteins (e.g., 
HA, NA, M2) are tabulated in the bioinformatic studies of 
7 H1N1, 8 H3N2 and 2 H5N1 isolates (Bui et al, 2007). In 
this analysis remarkably all but one Ab-epitope study was 
from animal experiments, but since then additional human 
antibody protectopes are being realized (Ekiert et al, 2009; 
Sui et al, 2009). This study was followed by a more 
encompassing evaluation of highly-conserved linear sites 
of 9 amino acids or longer, across all the strains of 
influenza (Heiny et al, 2007). Both studies revealed 
considerable conservation of sequence and antigen 
epitopes across the breadth of influenza proteins, with 
some 90 to 100% conserved and some already identified 
from animal studies as protective determinants (Bui et al, 
2007). For seasoned vaccine initiatives the mapping and in 
vivo evaluation of epitope combinations for multiple-point 
targeting of infection is now necessary for vaccine design. 
 
Examples of protective antibodies against conserved 
epitopes include those binding to the M2 protein 
tetrameric ectodomain (De Filette et al, 2008), site(s) on 
NA that disrupt sialidase release of budding virons from 
infected cells (Sandbulte et al, 2007) and of the HA stem 
that contains the proteolytic cleavage site and hydrophobic 
membrane fusion segment (Bui et al, 2007; Sui et al, 2009; 
Ekiert et al, 2009). In natural infections and vaccine 
antibody responses the conserved but poorly-immunogenic 
sites of the HA stalk must compete with the highly-
immunogenic and variable epitopes of the globular-head. 
Recent studies have shown the broadly protective value of 
human antibodies that target the pre-fusion structures of 
the HA stalk (Ekiert et al, 2009; Sui et al, 2009). As cross-
protective antibodies to the conserved stalk are developed 
in mice following immunization with constructs with 
deleted globular-head but not with complete HA, studies 
are now needed to evaluate heterotypic humoral responses 
to a variety of conserved influenza epitopes in the absence 
of competing HA immune-dominant globular-head 
antigens (Sagawa et al, 1996). More contentious is what 
role if any do antibodies directed at internal influenza 
antigens, such as in the highly-conserved NP protein, play 
in hetero(sub)typic protection. NP is expressed on the 
surface of influenza infected cells (Virelizier et al, 1977; 
Stitz et al, 1990; Prokudina and Semenova, 1991) and is a 
major target for cytotoxic T-lymphocytes (Stitz et al,  
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1990; Prokudina and Semenova, 1991). However, early 
studies indicated that NP did not protect against influenza 
infection
 (Stitz et al, 1990). Substantial antibody responses 
are generated to internal proteins by natural infection or 
vaccination (Couch, 2003). In mice, following vaccination 
with recombinant NP, both non-neutralizing and protective 
anti-NP antibodies are generated that reduce influenza 
virus titres and reduce mortality in influenza-infected mice 
passively treated with NP hyperimmune serum (Carragher 
et al, 2008). Similarly in a chicken study model, passively 
transferred anti-NP antibodies (and to a lesser extent 
antibodies to the polymerase complex proteins PA1, PB1, 
PB2) were found to protect against infection with highly-
pathogenic H7N3 influenza (Shahzad et al, 2008). It is 
important to determine if such responses are translatable to 
humans, and what role anti-NP antibodies play in 
heterosubtypic protection elicited by NP vaccines (Epstein 
et al, 2005; Price et al, 2009). It is also of interest to 
evaluate whether antibodies to infected cells expressing 
internal viral antigens, such as NP, may add to and 
complement other cross-typic responses (e.g., to M2e and 
HA stalk/fusion domains). 
 
Whether the rules of engagement and responses to the 
generation of protective heterosubtypic antibodies in 
humans mirror well-characterized immunodominant 
homotypic responses remains to be determined. Certainly a 
significant unknown is how to best present protectope 
antigens for vaccines to stimulate protective heterosubtypic 
antibody responses. This would be governed by a variety of 
factors, including the optimal selection of protein or peptide 
constructs, epitope combinations, presentation (e.g., with or 
without adjuvant) (Straight et al, 2008), route of 
administration (Price et al, 2009) and roles of antibody 
secreting plasma cell and memory B cell responses 
(Wrammert et al, 2008). The first point of order, however, 
needs to be a clear demonstration of the role and 
significance of heterosubtypic antibodies in cross-typic 
protection of humans for influenza. Certainly the exciting 
findings of Ekiert et al (2009) and Sui et al (2009) indicate 
the potential, but this needs to be further supported by a 
more comprehensive evaluation of the complement of 
conserved influenza epitopes.        
 
Thus, for more universal protection new approaches are 
required to target the many sites that are conserved across 
influenza proteins. However, because the immune responses 
to those sites are subverted by immune-dominant HA, and 
to a lesser extent NA antigens that form the centre-point of 
seasonal vaccines, new style constructs are needed that 
actually avoid those immunodominant sites. It would 
therefore be informative to examine heterosubtypic 
antibody responses for multiple viral constructs devoid of 
the regions that are the main focus of seasonal vaccines. The 
challenge is to test and evaluate a broad sampling of 
conserved influenza epitope combinations, including 
already indicated antibody protectopes, to substantiate the 
value of seasoned heterosubtypic antibody responses in 
broad protection of drifted and shifted influenzas. Studies of 
linear conserved regions can be made using recombinant 
protein fragments, peptides or DNA constructs before 
graduating to conformationally maintained recombinant and 
native viral protein constructs for the more difficult study of 
discontinuous conserved epitopes. Cross-strain antibody 
immune response comparisons of seasonal inactivated and 
live attenuated vaccines versus seasoned conserved antigen 
constructs will reveal the differences and similarities in their 
capacities for heterosubtypic protection to drive future 
vaccine initiatives. We envisage that if true value can be 
unequivocally established, future seasoned protectope 
vaccines will be used for the population at large to 
separately complement not replace current seasonal 
strategies. Together, these vaccines will systematically 
provide antibody protection to reduce the impact of 
emerging pathogenic and pandemic influenzas and reduce 
the considerable health and economic burden of epidemic 
influenzas. With comprehensive and synergistic targeting of 
conserved antibody epitopes in conjunction with strategies 
already raised for stimulating heterosubtypic T-cell 
responses (Doherty and Kelso, 2008; Lee et al, 2008) we are 
confident that vaccines for sustained and synergistic 
crosstypic influenza protection will be realized. Continued 
evolution and expansion of avian to human H5N1 and 
human to human 2009 H1N1 pandemic H1N1 virus, 
highlights the need for more universal vaccines to generate 
heterotypic protection for immune-naive individuals, and 
promote rapid heterosubtypic hyperimmune responses for 
passive therapies to meet ongoing and future challenges.   
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